Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies

被引：68
|
作者：
Gore, M. E. [1 ]
Larkin, J. M. G. [1 ]
机构：
[1] Royal Marsden Hosp, Dept Med, London SW3 6JJ, England
来源：
BRITISH JOURNAL OF CANCER | 2011年 / 104卷 / 03期
关键词：
chronic disease; combinatorial therapy; renal cell carcinoma; sequential therapy; sunitinib malate; targeted agents; PHASE-II TRIAL; INTERFERON-ALPHA; 1ST-LINE TREATMENT; DOUBLE-BLIND; SUNITINIB; CANCER; SORAFENIB; TEMSIROLIMUS; BEVACIZUMAB; EVEROLIMUS;
D O I：
10.1038/sj.bjc.6606084
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Optimum efficacy is the primary goal for any cancer therapy, and entails controlling tumour growth and prolonging survival as far as possible. The prognosis for patients with metastatic renal cell carcinoma (mRCC) has greatly improved with the introduction of targeted therapies. This review examines the development and efficacy of targeted agents for the management of mRCC, the challenge; offered by their rapid emergence, and discusses how mRCC treatment may evolve in the future. Improvements in progression-free survival and overall survival rates, observed with targeted agents, indicate that it may now be possible to change mRCC from a rapidly fatal and largely untreatable condition into a chronic disease. The major challenges to further advances in targeted therapy for mRCC include overcoming drug resistance, identifying the most effective sequence or combination of targeted agents, optimising clinical trial design and managing the cost of treatment. British Journal of Cancer (2011) 104, 399 - 406. doi:10.1038/sj.bjc.6606084 www.bjcancer.com (C) 2011 Cancer Research UK
引用
收藏
页码：399 / 406
页数：8
相关论文
共 50 条
  • [1] Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies
    M E Gore
    J M G Larkin
    British Journal of Cancer, 2011, 104 : 399 - 406
  • [2] Sequential use of targeted agents in the treatment of renal cell carcinoma
    Hutson, Thomas E.
    Bukowski, Ronald M.
    Cowey, C. Lance
    Figlin, Robert
    Escudier, Bernard
    Sternberg, Cora N.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 77 (01) : 49 - 63
  • [3] Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Clinical Evidence
    Hutson, Thomas E.
    ONCOLOGIST, 2011, 16 : 14 - 22
  • [4] Sunitinib and other targeted therapies for renal cell carcinoma
    Powles, T.
    Chowdhury, S.
    Jones, R.
    Mantle, M.
    Nathan, P.
    Bex, A.
    Lim, L.
    Hutson, T.
    BRITISH JOURNAL OF CANCER, 2011, 104 (05) : 741 - 745
  • [5] Targeted therapies for renal cell carcinoma: more gains from using them again
    Gan, H. K.
    Seruga, B.
    Knox, J. J.
    CURRENT ONCOLOGY, 2009, 16 : S47 - S53
  • [6] Targeted therapies for renal cell carcinoma
    Villanueva, Mary Lee H.
    Hauke, Ralph
    TARGETED ONCOLOGY, 2007, 2 (01) : 7 - 16
  • [7] Targeted therapies for renal cell carcinoma
    Mary Lee H. Villanueva
    Ralph Hauke
    Targeted Oncology, 2007, 2 : 7 - 16
  • [8] Targeted therapies for renal cell carcinoma: understanding their impact on survival
    Pal, Sumanta Kumar
    Figlin, Robert A.
    TARGETED ONCOLOGY, 2010, 5 (02) : 131 - 138
  • [9] Management of metastatic renal cell carcinoma in the era of targeted therapies
    Webber, K.
    Cooper, A.
    Kleiven, H.
    Yip, D.
    Goldstein, D.
    INTERNAL MEDICINE JOURNAL, 2011, 41 (08) : 594 - 605
  • [10] Update on targeted therapies for clear cell renal cell carcinoma
    Singer, Eric A.
    Gupta, Gopal N.
    Srinivasan, Ramaprasad
    CURRENT OPINION IN ONCOLOGY, 2011, 23 (03) : 283 - 289
12345